The first clinical evidence linking PCSK9 and cardiovascular diseases (CVD) discovered: patients with gain-of-function mutations in PCSK9 showed significantly increased serum levels of LDL-C, decreased levels of LDL receptors on hepatocytes, and was prone to experiencing premature cardiovascular events (24). Here, LDLR is linked to cardiovascular disorder.